Congress creates diabetes oversight board to cut through federal silos
H.R. 9149 — National Diabetes Project Act · Filed by John James (R-MI) · Introduced Jun 4, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes a National Diabetes Project within the Department of Health and Human Services to create a coordinated federal strategy for diabetes prevention, research, and care. It creates an advisory council with federal and non-federal experts to evaluate existing diabetes programs, recommend improvements, and produce annual reports to Congress on progress and priorities through 2036.
Why we flagged it
The bill's core function is establishing an interagency coordination mechanism and advisory structure for diabetes policy, not direct treatment or research funding. It is a governance and planning instrument designed to improve federal program alignment and transparency.
What the text implies
- The bill mandates data-sharing across federal agencies on diabetes, which could improve epidemiological understanding but also creates a centralized federal diabetes dataset that may raise privacy considerations if not carefully governed.
- By requiring evaluation of 'all federally funded efforts' and recommending programs be 'eliminated, coordinated, or condense[d],' the bill implicitly authorizes the Secretary to recommend consolidation or closure of existing programs, which could affect beneficiaries of smaller or redundant initiatives.
- The advisory council's explicit focus on 'reducing the financial impact of diabetes on Medicare' signals cost-containment as a priority alongside care improvement, which may create tension between access expansion and budget control.
Who it affects
The bill creates a public health coordination mechanism that consolidates fragmented federal diabetes efforts, mandates transparency through public advisory meetings and annual congressional reports, and explicitly prioritizes reducing health disparities in underserved populations. Citizens with diabetes and their families gain clearer access to coordinated care and research, and the public gains visibility into federal spending effectiveness.
Who stands to gain
- pharmaceutical companies (diabetes treatment development)
- medical device manufacturers (diagnostic and monitoring equipment)
- healthcare providers and systems (coordinated care expansion)
- research institutions (federally funded diabetes research)
Named in the bill
Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare & Medicaid Services, National Institutes of Health, Food and Drug Administration, Indian Health Service, Department of Veterans Affairs, National Science Foundation, Agency for Healthcare Research and Quality, Administration on Aging
Where it stands
- Jun 4, 2026 — Introduced · Congress.gov: “Introduced in House”
- Jun 4, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 9, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress creates diabetes oversight board to cut through federal silos” QuorumCivic. https://share.quorumcivic.app/bill/119/hr9149 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.